郭春磊，1983.09-，南開大學(xué)理學(xué)博士學(xué)位。2017年至今就職于新鄉(xiāng)醫(yī)學(xué)院醫(yī)學(xué)檢驗(yàn)學(xué)院，目前的研究方向?yàn)槟[瘤免疫，主要從事腫瘤干細(xì)胞與腫瘤微環(huán)境之間相互調(diào)控的分子機(jī)制及腫瘤轉(zhuǎn)移和復(fù)發(fā)過程的機(jī)制研究。累計(jì)主持國家自然科學(xué)基金1項(xiàng)，河南省高校重點(diǎn)科研項(xiàng)目1項(xiàng)；在Theranostics、International Journal of Pharmaceutics、Scientific Reports等雜志上發(fā)表論文5篇。

發(fā)表SCI論文一覽表（#為第一作者，*為通訊作者）

1. Guo C^#, Chen Y^#, Gao W, Chang A, Ye Y, Shen W, Luo Y, Yang S, Sun P, Xiang R^*, Li N^*. Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models. Theranostics. 2017 Jan 26;7(3):775-788. IF=8.854

2. Hou J, Guo C, Shi Y, Liu E, Dong W, Yu B, Liu S, Gong J. A novel high drug loading mussel-inspired polydopamine hybrid nanoparticle as a pH-sensitive vehicle for drug delivery. Int J Pharm. 2017 Nov 25;533(1):73-83. IF= 3.649

3. Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T^*, Rong X^*. Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis. Sci Rep. 2015 Nov 26;5:16599. IF= 5.228

4. Zhen Y, Xinghui Z, Chao W, Yi Z, Jinwen C, Ruifang G, Chao Z, Min Z, Chunlei G, Yan F, Lingfang D, Long S, Wenzhi S, Xiaohe L, Rong X. Several microRNAs could predict survival in patients with hepatitis B-related liver cancer. Sci Rep. 2017 Mar 21;7:45195. IF= 5.228

5. Shen W^#, Xie J^#, Zhao S, Du R, Luo X, He H, Jiang S, Hao N, Chen C, Guo C, Liu Y, Chen Y, Sun P, Yang S, Luo N, Xiang R^*, Luo Y^*. ICAM3 mediates inflammatory signaling to promote cancer cell stemness. Cancer Lett. 2018 May 28;422:29-43. IF= 6.375

   
   

   主持的重大科研項(xiàng)目：

6. FBF1促進(jìn)乳腺癌細(xì)胞干性和侵襲轉(zhuǎn)移的機(jī)制研究，郭春磊，國家自然科學(xué)基金2019.01-2021.12，No. 81802967，21萬元。